Drug Profile

Maraviroc/atorvastatin - Healthbio Therapeutics

Latest Information Update: 31 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator HealthBio
Class Amides; Antihyperlipidaemics; Antiretrovirals; Cyclohexanes; Esters; Fatty acids; Fluorobenzenes; Heptanoic acids; Pyrroles; Small molecules; Triazoles
Mechanism of Action CCR5 receptor antagonists; HMG-CoA reductase inhibitors; Virus internalisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

20 Feb 2025 HealthBio announced the intention to submit a New Drug Application to the US FDA for Post-acute-COVID-19-syndrome
12 Feb 2025 HealthBio has patent protection for the combination of Maraviroc and Atorvastatin
12 Feb 2025 HealthBio has patent protection for the use of all CCR5 antagonists including maraviroc to treat Long COVID

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com